Novo Nordisk ADR [NYSE: NVO] loss -3.48% on the last trading session, reaching $74.34 price per share at the time.
If compared to the average trading volume of 9.99M shares, NVO reached a trading volume of 8054788 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Novo Nordisk ADR [NVO]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for NVO shares is $98.61 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on NVO stock is a recommendation set at 2.06. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BMO Capital Markets have made an estimate for Novo Nordisk ADR shares, keeping their opinion on the stock as Market Perform, with their previous recommendation back on April 17, 2025. The new note on the price target was released on March 13, 2025, representing the official price target for Novo Nordisk ADR stock.
The Average True Range (ATR) for Novo Nordisk ADR is set at 2.56, with the Price to Sales ratio for NVO stock in the period of the last 12 months amounting to 5.74. The Price to Book ratio for the last quarter was 16.46, with the Price to Cash per share for the same quarter was set at 1.79. Price to Free Cash Flow for NVO in the course of the last twelve months was 17.52 with Quick ratio for the last quarter at 0.56.
Trading performance analysis for NVO stock
Novo Nordisk ADR [NVO] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -6.29. With this latest performance, NVO shares gained by 15.49% in over the last four-week period, additionally sinking by -31.55% over the last 6 months – not to mention a drop of -47.83% in the past year of trading.
#####
Novo Nordisk ADR [NVO]: A deeper dive into fundamental analysis
Novo Nordisk ADR’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.56 and a Current Ratio set at 0.74.
Novo Nordisk ADR [NVO]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for NVO. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Novo Nordisk ADR go to 18.78%.
An analysis of Institutional ownership at Novo Nordisk ADR [NVO]
The top three institutional holders of NVO stocks are: JENNISON ASSOCIATES LLC with ownership of 21.22 million shares, which is approximately 0.476%. FMR LLC, holding 19.49 million shares of the stock with an approximate value of $$2.78 billion in NVO stocks shares; and FMR LLC, currently with $$2.09 billion in NVO stock with ownership which is approximately 0.3272%.
